Verona Pharma’s Ohtuvayre: Strong Performance and Growth Potential Drive Buy Rating
Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...
Verona Pharma price target raised to $60 from $42 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...
Investing14d
Roth/MKM initiates coverage on Verona Pharma stock with Buy rating and strong upside potential
The bullish stance is based on the potential of Verona Pharma's Ohtuvayre™, which is expected to address a substantial total addressable market (TAM) of approximately 8.6 million symptomatic patients ...
FiercePharma16d
Breaking down the 55 new drug approvals of 2024
A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these ...
Investing17d
Verona Pharma stock target increased, keeps buy on Q4 sales
The adjustment follows Verona Pharma's announcement of fourth-quarter sales for Ohtuvayre, which totaled approximately $36 million, unaudited. These figures surpassed both Truist Securities' estimate ...